[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479985":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":51,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":65,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MRD level group",null,"Participants will be defined as diagnosed with multiple myeloma",[13],"Diagnostic Test: Standard of care",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Standard of care","Participants will not receive any intervention in this study. Participants will receive standard of care therapy",[9],[21],{"name":22,"affiliation":5,"role":23},"Rayan Kaedbey","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Rayan Kaedbey, MD FRCPC","CONTACT","514-340-8222","rayan.kaedbey.med@ssss.gouv.qc.ca",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Jewish General Hospital","RECRUITING","Montreal","Quebec","H3T 1E2","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-73.58781,45.50884,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":49,"email":50},"Rayan Kaedbey, MD","514 340 8222","28799","rayan.kaedbey@mcgill.ca",{"type":23,"investigatorFullName":22,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal Investigator","100479985",false,"NCT05530096","Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD","Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.","TELO - DMRD","Inclusion Criteria:\n\n* Confirmed MM diagnosis\n* Transplant eligible patients in a first remission\n* Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)\n* Availability of deidentified patient's demographic and clinical follow up data\n* Receiving standard of care treatment\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Failure to meet inclusion criteria","ALL","18 Years",{"count":63,"type":64},70,"ESTIMATED","24 Months","OBSERVATIONAL","The purpose :\n\nDetect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.",[69],"Multiple Myeloma","2025-03-30",{"date":72,"type":73},"2025-04-03","ACTUAL",{"date":75,"type":73},"2024-05-01",{"date":77,"type":64},"2028-09",{"name":5,"class":6},1]